SEARCH

SEARCH BY CITATION

References

  • 1
    Lynch TJ , Bell DW , Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 212939.
  • 2
    Paez JG , Jänne PA , Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497500.
  • 3
    Soda M , Choi YL , Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 5616.
  • 4
    Mitsudomi T , Morita S , Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 1218.
  • 5
    Maemondo M , Inoue A , Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 23808.
  • 6
    Kwak EL , Bang YJ , Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693703.
  • 7
    Jackman D , Pao W , Riely GJ et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010; 28: 35760.
  • 8
    Shaw AT , Yeap BY , Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12: 100412.
  • 9
    Pao W , Chmielecki J . Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010; 10: 76074.
  • 10
    Engelman JA , Jänne PA . Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008; 14: 28959.
  • 11
    Yano S , Wang W , Li Q et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma cells with EGF receptor mutations. Cancer Res 2008; 68: 947987.
  • 12
    McCoy MS , Toole JJ , Cunningham JM , Chang EH , Lowy DR , Weinberg RA . Characterization of a human colon/lung carcinoma oncogene. Nature 1983; 302: 7981.
  • 13
    Hammerman PS , Sos ML , Ramos AH et al. Mutations in the DDR kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011; 1: 7889.
  • 14
    Bergethon K , Shaw AT , Ignatius Ou SH et al. ros1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30: 86370.
  • 15
    Fukuoka M , Yano S , Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21: 223746.
  • 16
    Herbst RS , Heymach JV , Lippman SM . Lung cancer. N Engl J Med 2008; 359: 136780.
  • 17
    Schiller JH , Harrington D , Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 928.
  • 18
    Ohe Y , Ohashi Y , Kubota K et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007; 18: 31723.
  • 19
    Inamura K , Takeuchi K , Togashi Y et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009; 22: 50815.
  • 20
    Kobayashi S , Boggon TJ , Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 78692.
  • 21
    Pao W , Miller VA , Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
  • 22
    Choi YL , Soda M , Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363: 17349.
  • 23
    Engelman JA , Zejnullahu K , Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 103943.
  • 24
    Katayama R , Khan TM , Benes C et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011; 108: 753540.
  • 25
    Yamamoto C , Basaki Y , Kawahara A et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 2010; 70: 871525.
  • 26
    Sequist LV , Waltman BA , Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
  • 27
    Faber A , Corcoran RB , Ebi H et al. BIM expression in treatment naïve cancers predicts responsiveness to kinase inhibitors. Cancer Discov 2011; 1: 35265.
  • 28
    Nakamura T , Nishizawa T , Hagiya M et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 4403.
  • 29
    Nakamura T , Sakai K , Nakamura T , Matsumoto K . Hepatocyte growth factor twenty years on: much more than a growth factor. J Gastroenterol Hepatol 2011; 26 (Suppl 1): 188202.
  • 30
    Harvey P , Warn A , Newman P , Perry LJ , Ball RY , Warn RM . Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas. J Pathol 1996; 180: 38994.
  • 31
    Olivero M , Rizzo M , Madeddu R et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996; 74: 18628.
  • 32
    Tokunou M , Niki T , Eguchi K et al. c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma. Am J Pathol 2001; 158: 145163.
  • 33
    Stabile LP , Lyker JS , Land SR , Dacic S , Zamboni BA , Siegfried JM . Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. Carcinogenesis 2006; 27: 154755.
  • 34
    Nakamura T , Matsumoto K , Kiritoshi A , Tano Y , Nakamura T . Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res 1997; 57: 330513.
  • 35
    Grotegut S , von Schweinitz D , Christofori G , Lehembre F . Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J 2006; 25: 353445.
  • 36
    Kuba K , Matsumoto K , Date K , Shimura H , Tanaka M , Nakamura T . HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000; 60: 673743.
  • 37
    Rong S , Segal S , Anver M , Resau JH , Vande Woude GF . Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci USA 1994; 91: 47315.
  • 38
    Ichimura E , Maeshima A , Nakajima T , Nakamura T . Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996; 87: 10639.
  • 39
    Siegfried JM , Weissfeld LA , Singh-Kaw P , Weyant RJ , Testa JR , Landreneau RJ . Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 1997; 57: 4339.
  • 40
    Wang W , Li Q , Yamada T et al. Crosstalk to stromal fibroblasts induces resistance of lung cancer to EGFR tyrosine kinase inhibitors. Clin Cancer Res 2009; 15: 66308.
  • 41
    Turke AB , Zejnullahu K , Wu YL et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17: 7788.
  • 42
    Yano S , Yamada T , Takeuchi S et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 2011; 6: 20117.
  • 43
    Suda K , Murakami I , Katayama T et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010; 16: 548998.
  • 44
    Onitsuka T , Uramoto H , Nose N et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 2010; 68: 198203.
  • 45
    Yasuda H , Kobayashi S , Costa DB . EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2012; 13: e2331.
  • 46
    Yamada T , Matsumoto K , Wang W et al. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res 2010; 16: 17483.
  • 47
    Wang W , Li Q , Takeuchi S et al. E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells. Clin Cancer Res 2012; 18: 166371.
  • 48
    Guix M , Faber AC , Wang SE et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. Clin Invest 2008; 118: 260919.
  • 49
    Yano S , Nakataki E , Ohtsuka S et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res 2005; 15: 10711.
  • 50
    Sharma SV , Lee DY , Li B et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 6980.
  • 51
    Pirker R , Pereira JR , Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 152531.
  • 52
    Pirker R , Pereira JR , von Pawel J et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13: 3342.
  • 53
    Yamada T , Takeuchi S , Kita K et al. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. J Thorac Oncol 2012; 7: 27280.
  • 54
    Sasaki T , Okuda K , Zheng W et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010; 70: 1003843.
  • 55
    Sasaki T , Koivunen J , Ogino A et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011; 71: 605160.
  • 56
    Heuckmann JM , Hölzel M , Sos ML et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 2011; 17: 7394401.
  • 57
    Katayama R , Shaw AT , Khan TM et al. Mechanisms of Acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012; 4: 120ra17.
  • 58
    Yamada T , Takeuchi S , Nakade J et al. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells. Clin Cancer Res, in press.
  • 59
    Sakamoto H , Tsukaguchi T , Hiroshima S et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011; 19: 67990.
  • 60
    Okamoto W , Okamoto I , Tanaka K et al. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther 2010; 9: 278592.
  • 61
    Jin H , Yang R , Zheng Z et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68: 43608.
  • 62
    Donev IS , Wang W , Yamada T et al. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res 2011; 17: 22609.